1492 Capital Management LLC acquired a new stake in Astrana Health, Inc. (NASDAQ:ASTH - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 26,857 shares of the company's stock, valued at approximately $847,000.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Marshall Wace LLP bought a new stake in shares of Astrana Health during the fourth quarter valued at approximately $2,821,000. Barclays PLC increased its position in Astrana Health by 3.4% in the 4th quarter. Barclays PLC now owns 79,543 shares of the company's stock valued at $2,507,000 after acquiring an additional 2,627 shares during the period. Renaissance Technologies LLC increased its position in Astrana Health by 217.6% in the 4th quarter. Renaissance Technologies LLC now owns 217,900 shares of the company's stock valued at $6,870,000 after acquiring an additional 149,300 shares during the period. Invesco Ltd. raised its stake in Astrana Health by 6.9% during the 4th quarter. Invesco Ltd. now owns 258,520 shares of the company's stock valued at $8,151,000 after acquiring an additional 16,717 shares in the last quarter. Finally, Envestnet Asset Management Inc. boosted its position in Astrana Health by 19.9% during the 4th quarter. Envestnet Asset Management Inc. now owns 7,124 shares of the company's stock worth $225,000 after acquiring an additional 1,184 shares during the period. 52.77% of the stock is owned by institutional investors and hedge funds.
Astrana Health Stock Performance
NASDAQ:ASTH opened at $31.38 on Friday. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60. The company has a 50-day moving average of $32.25 and a 200-day moving average of $39.67. Astrana Health, Inc. has a twelve month low of $23.12 and a twelve month high of $63.20. The firm has a market cap of $1.57 billion, a price-to-earnings ratio of 24.14, a price-to-earnings-growth ratio of 1.37 and a beta of 1.04.
Astrana Health (NASDAQ:ASTH - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of $0.22 by ($0.37). The business had revenue of $665.21 million for the quarter, compared to the consensus estimate of $617.24 million. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. Analysts forecast that Astrana Health, Inc. will post 1.15 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on the company. Robert W. Baird lowered their price target on Astrana Health from $86.00 to $50.00 and set an "outperform" rating on the stock in a report on Monday, March 3rd. Bank of America lowered their target price on shares of Astrana Health from $55.00 to $49.00 and set a "buy" rating on the stock in a research note on Tuesday, March 4th. Truist Financial dropped their price target on shares of Astrana Health from $50.00 to $46.00 and set a "buy" rating on the stock in a research report on Tuesday, March 18th. Barclays assumed coverage on shares of Astrana Health in a report on Tuesday, April 1st. They issued an "equal weight" rating and a $36.00 price objective for the company. Finally, Stifel Nicolaus dropped their target price on Astrana Health from $70.00 to $56.00 and set a "buy" rating on the stock in a report on Thursday, February 20th. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Astrana Health has an average rating of "Moderate Buy" and an average target price of $53.29.
Check Out Our Latest Analysis on ASTH
Astrana Health Company Profile
(
Free Report)
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Astrana Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astrana Health wasn't on the list.
While Astrana Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
